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Purpose:  To  screen  for  possible  disease-causing  mutations  in  rhodopsin  (RHO),  pre-mRNA  processing  factor  31
(PRPF31), retinitis pigmentosa 1 (RP1), and inosine monophosphate dehydrogenase 1 (IMPDH1) genes in Indian patients
with isolated and autosomal dominant forms of retinitis pigmentosa (adRP). Information on such data is not available in
India and hence this study was undertaken.
Methods: Blood samples were obtained from 48 isolated and 53 adRP patients, who were recruited for the study. Each
patient underwent a detailed clinical examination. Genomic DNA was extracted from the blood samples and screened for
mutations in four genes using an ABI3100 Avant genetic analyzer. Reverse transcriptase polymerase chain reaction was
performed to amplify the mutated (IVS6+1G/A) mRNA of PRPF31 in a two-generation adRP family.
Results: Of the 101 probands analyzed, three harbored possible disease-causing mutations. Pathogenic changes were
observed in RHO and PRPF31. A RHO mutation, p.Gly106Arg, was found in an isolated RP patient with sectoral RP.
Two novel, heterozygous mutations were identified in PRPF31: p.Lys120GlufsX122 in an isolated RP patient and a splice
site  mutation,  IVS6+1G/A  in  an  adRP  patient.  However,  no  disease-causing  changes  were  observed  in  RP1  and
IMPDH1.
Conclusions: We screened RHO, PRPF31, RP1, and IMPDH1 and identified causative mutations in 4% of isolated and
2% of adRP patients from India. To the best of our knowledge, this is the first report to identify frequencies of mutations
in isolated and adRP patients in India.
Retinitis pigmentosa (RP) is a group of inherited retinal
degenerative  disorders  characterized  by  progressive
degeneration  of  the  midperipheral  retina,  leading  to  night
blindness, visual field constriction, and eventual loss of visual
acuity. It is one of the leading causes of blindness in adults
with an incidence of around 1 in 3,500 worldwide [1]. Clinical
manifestations include pigment deposition in the retina and
attenuation of retinal blood vessels followed by atrophy of the
retinal  pigment  epithelium  [2].  Electroretinogram  (ERG)
changes are present with abnormalities of both rod and cone
ERGs, but rod ERGs are more affected than cone ERGs [3].
In  advanced  RP  both  rod  and  cone  ERG  responses  are
undetectable. RP can be inherited in an autosomal dominant
(ad), recessive (ar), or x-linked (xl) manner, as well as in
digenic, mitochondrial, or simplex patterns. Most patients
with RP are isolated or sporadic with no known affected
relatives, although some of these may have inheritances that
are  autosomal  or  X-linked  recessive  or  dominant  with
incomplete penetrance. Despite having similar characteristics,
there is a wide spectrum of clinical and genetic heterogeneity
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between  the  different  modes  of  inheritance.  RP  involves
nearly 37 genes (Table 1;RetNet). However, this is only a
partial representation of the total number of genes since it is
believed that more than 60% of RP genes have yet to be
identified [4].
According to various reports, adRP represents between
15% and 35% of all RP cases. These values were derived from
different studies, with the highest value being found in the
United  States  [5]  and  the  lowest  in  southern  Europe  [6].
However, accurate data on the frequency of RP in India is not
available. To date, about 17 genes have been identified as
causative of adRP. Rhodopsin (RHO) is the most frequently
reported adRP gene, contributing to 20%–25% of cases [7],
followed by pre-mRNA processing factor 31 (PRPF31) (2%–
8% of adRP cases) [8,9], retinitis pigmentosa 1 (RP1) (5%–
10%)  [10],  and  inosine  monophosphate  dehydrogenase  1
(IMPDH1) (5%–10%) [11]. The frequency of mutations in
these  genes  has  been  documented  for  many  populations
around the world, but not for patients from India.
All of the aforenamed genes, excluding PRPF31, have
been reported as disease-causing for arRP. IMPDH1 not only
causes  adRP  but  also  Leber  congenital  amaurosis  (LCA)
[12]. Currently, treatment for RP is unavailable; however,
animal models for a variety of retinal degenerations have been
successfully rescued, using gene therapy approaches. Based
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1105on this success, it is anticipated that such treatments may
become available for patients. Therefore, we undertook the
first  mutational  analysis  of  four  most  frequently  reported
adRP genes in our patients.
METHODS
Study participants were selected after clinical examination
(retina clinic) and pedigree analysis (genetic clinic) at Sankara
Nethralaya.  Clinical  tests  included  Humphrey  perimetry,
fundus photography, and electroretinogram (ERG). A detailed
pedigree was taken from the probands. Criteria for selecting
adRP families were based on the occurrence of at least two
affected generations with both sexes along with evidence of
male to male transmission. The details of the patients and
controls participated in the current study are given in Table 2.
Genomic DNA was extracted from each 3 ml blood sample
collected  from  48  isolated  and  53  adRP  patients  and  75
unrelated  controls  using  standard  phenol-chloroform
methodology.  Informed  consent  was  obtained  from  all
participants,  and  the  research  adhered  to  the  tenets  of
Declaration of Helsinki and was approved by the hospital
Internal  Review  Board.  All  the  coding  regions  and  the
adjacent flanking intronic sequences of RHO, PRPF31, and
IMPDH1  and  the  exons  harboring  previously  reported
mutations of the RP1 gene, namely exons 4F, 4G, and 4H of
RP1 were amplified by polymerase chain reaction (PCR). The
primers  and  the  amplification  conditions  used  were  as
reported previously [11,13-15]. PCR amplified products were
electrophoresed at 100 v for 30 min on 2% ethidium bromide-
agarose  gels.  The  ethidium  bromide-stained  gels  were
captured  by  the  gel  documentation  system  ImageMasterR
VDS (Amersham Pharmacia Biotech, Piscataway, NJ) using
the  Liscap  software  and  analyzed  using  the  Imagemaster
Totallab gel documentation system. The PCR products were
directly sequenced with ABI 3100 Avant Genetic Analyzer
(Applied  Biosystems,  Foster  City,  CA)  using  the  same
oligomers  employed  in  the  PCR  reactions.  The  patients'
sequences  were  compared  to  known  RHO  (GenBank
NM_000539),  PRPF31  (GenBank  NM_015629),  RP1
(GenBank  NM_006269),  and  IMPDH1  (GenBank
NM_000883) sequences.
Reverse  transcriptase-polymerase  chain  reaction
reactions: RNA was isolated from 10 ml of heparinized blood
samples, for each of the five members of an adRP family
(family A) having the PRPF31 (IVS6+1G/A) mutation. RNA
isolation was done using Trizol reagent (Sigma-Aldrich, St.
Louis, MO), according to the manufacturer’s instructions.
Blood (10 ml) was collected from each individual. DNase-
TABLE 1. NUMBER OF RETINITIS PIGMENTOSA GENES AND LOCI
Mapped and identified genes CA4, CRX, FSCN2, GUCA1B, IMPDH1, NR2E3,
NRL, PRPF3, PRPF8, PRPF31, PRPH2, RHO,
ROM1, RP1, RP9, SEMA4A, TOPORS, ABCA4,
CERKL, CNGA1, CNGB1, CRB1, LRAT, MERTK,
NR2E3, PDE6A, PDE6B, PRCD, PROM1, RGR,
RLBP1, RPE65, SAG, TULP1, USH2A, RP2,
RPGR
37




Tremendous research in the field of RP allowed the identification of nearly 47 genes. However, mutations in 37 genes are known
to cause adRP and 10 adRP genes have been mapped but not identified yet (RetNet).





Isolated 32 16 35 (range 12-60 years). RP
adRP 28 25 30.5 (range 3-61years) RP
Controls 50 25 61.5 (range 42-70 years) normal
Of 151 individuals recruited for the study, 101 were RP patients (48 isolated and 53 adRP) and 50 were unrelated healthy
individuals. All the patients demonstrated typical features of RP. The average age has been calculated for all three groups of
participants and is as tabulated above. However to overcome the problem of late onset of the disease in control group and to
ensure the presence of the normal individuals in the same, we recruited individuals of age group between 42-70 years.
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Average age Gendertreated  RNA,  cloned  MMLV  reverse  transcriptase  (USB,
Cleveland,  OH)  and  random  hexamers  (Amersham
Biosciences, Piscataway, NJ) were used to generate cDNA by
reverse transcription-polymerase chain reaction (RT–PCR).
The transcribed PRPF31 fragment from exon 3 to exon 8 was
amplified using the following paired primers (forward, 5'-
AAG TGA TGG GAC CAG TGG AG-3'; reverse, 5'-GTA
GAC  GAG  AAG  CCC  GAC  AG-3')  and  the  conditions
previously reported [16].The thermocycling profile was as
follows: RT reaction (50 °C for 60 min, 80 °C for 2 min),
followed by a three-step touchdown PCR (94 °C for 50 s; 65
°C for 1 min, drop 1 °C per cycle; 72 °C for 1 min) for 10
cycles, followed by a three-step PCR (94 °C for 50 s, 58 °C
for 1 min, 72 °C for 1 min) for 24 cycles.
RESULTS
Disease-causing mutations were identified in three out of 101
unrelated RP patients screened. We observed a heterozygous
TABLE 3. ISOCODING CHANGES AND POLYMORPHISMS IDENTIFIED.
Gene Variations Location Frequency
RHO c.232+4C/T Intronic 3^ 1* 2$
–26 A/G Intronic 1^ 1* 2$
PRPF31 c.238+93T/C Intronic 4^ 2* 3$
c.322+21G/A Intronic 3^ -* 1$
c.420+81T/C Intronic 12^ 8* 6$
c.420+82C/G Intronic 9^ 14* 4$
c.499+55G/A Intronic 1^ -* 2$
RP1 p. Arg 872 His Intronic 27^ 20* 14$
IMPDH1 c.383+33C/T Intronic 1^ 1* 1$
c.383+54delG Intronic 3^ 1* 2$
p.Leu244Leu Coding 13^ 7* 5$
p.Gln427Gln Coding 5^ 1* 2$
p.Ala440Ala Coding 1^ -* 1$
The polymorphisms identified in RHO, PRPF31, and RP1
were found in the noncoding or intronic regions. However, in
IMPDH1, out of 5 polymorphisms, two were in the intronic
region and the remaining three were in the exonic region
(isocoding changes). Abbreviations: The "^" symbol denotes
isolated, the "*" denotes adRP and the "$" symbol denotes
controls.
Figure 1. Clinical and molecular features of the proband (L2:50) with the p.Gly106Arg mutation. A: Pedigree showing the isolated form of
the disease. B: Genomic DNA sequences (reverse) of a part of the RHO gene of L2:50 displaying the p.Gly106Arg mutation (top) and of a
normal subject (bottom). The rectangular box shows the position of a heterozygous change at nucleotide 316 (c.316G/A, but the sequence
shows the reverse sequence boxed as Y). C: Visual field test reveals a sectoral form of RP. D: Fundus (right eye) photograph showing mild
retinitis pigmentosa changes.
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1107p.Gly106Arg mutation in RHO as well as two heterozygous
mutations in PRPF31: p.Lys120GlufsX122 and c.527+1G/A.
None of these changes were found in 75 unrelated healthy
controls.
p.Gly106Arg  (c.316G/A)—A  missense  change,
p.Gly106Arg  was  identified  (Figure  1)  in  an  isolated  RP
patient (L2:50). However this change was not seen in any of
the other family members or in 75 unrelated controls. Two
intronic  changes,  c.232+4C/T  and  –26  A/G,  were  also
detected in the study group.
L2:50, a 44-year-old woman from southern India, had a
two-year history of visual disability. She also had a history of
night blindness for 11/2 years but had no history of night
blindness in her family. Upon examination, her vision was 6/9;
N6 in the right eye and 6/12+2; N6 in the left eye. Vision
improved with – 0.50 DC X 90° to 6/6−1 and in the left eye –
0.50 DS / – 0.50 DC X 120° to 6/6. Near vision was N6 with
+1.50 DS. She was orthophoric; ocular movements were full,
free,  and  painless.  Slit-lamp  examination  revealed  no
abnormality except early posterior subcapsular cataract in
both eyes. Intraocular pressure with applanation tonometry
Figure 2. Electropherograms displaying
a  novel  PRPF31  mutation,
p.Lys120GlufsX122.  Genomic  DNA
sequences (reverse primer) of a part of
PRPF31  from  a  patient  with  the
p.Lys120GlufsX122 mutation (top) and
from  a  normal  subject  (bottom).  The
rectangular box shows the position of a
heterozygous  deletion  of  two
nucleotides at codon 120 (c. c.358_359
del  AA,  but  the  sequence  shows  the
reverse sequence boxed as TT).
Figure  3.  Pedigree  of  family  A
harboring  a  IVS6+1G/A  mutation  in
PRPF31.  The  change  in  the  genomic
DNA  sequence  was  observed  in  two
affected patients and an asymptomatic
individual.  Normal  individuals  are
shown  as  clear  circles  (females)  or
squares  (males),  and  affected
individuals are shown as solid symbols.
The clear square with the symbol “?”
indicates an asymptomatic carrier.
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Fundus examination with indirect ophthalmoscopy after full
dilatation revealed a normal disc. There were sectoral lesions
of bony corpuscles seen in the inferotemporal quadrant of both
eyes .The patient was given the clinical diagnosis of bilateral
sectoral RP. Humphrey visual field examination was done in
both  eyes.  It  showed  superior  constriction  of  the  fields
corresponding to inferior sectoral RP. ERG showed reduced
rod and cone response in both eyes consistent with sectoral
RP. None of the other family members were affected.
PRPF31 screening: We identified two novel pathogenic
changes: 1) p.Lys120GlufsX122 (GenBank DQ383415) in an
isolated  RP  case  (N1:51);  and  2)  IVS6+1G/A  (GenBank
DQ374434)  in  an  adRP  family  (family  A).  Five
nonpathogenic  intronic  variations  (Table  3)  were  also
identified in the study group.
p.Lys120GlufsX122 (c.358_359 del AA)—The deletion
of two nucleotides AA at codon 120 in exon 5 (Figure 2) of
PRPF31  leading  to  a  frameshift  was  observed  in  patient
N1:51. The truncated protein consisted of 122 amino acids
with  three  novel  amino  acids  before  the  stop  codon.  The
patient,  N1:51,  could  not  be  contacted,  therefore  detailed
clinical examination of the proband and genetic analysis for
the N1:51 family could not be performed.
IVS6+1G/A (c.358_359del AA)—The proband with this
splice site mutation was the child of an affected mother and
unaffected father. Upon further analysis of genomic DNA of
other members of family A (Figure 3), we found the mutation
in affected members, I-1 and II-1, and a clinically normal
individual,  II-  2,  but  not  in  other  two  clinically  normal
individuals,  I-2  and  II-3.  Individual  II-2  may  not  have
manifestation for two reasons: either the child was too young
(3.5 years) to manifest the disease, or there was incomplete
penetrance. To test whether the splice-site mutation leads to
a  defective  mRNA,  we  performed  RT–PCR  to  amplify
PRPF31  cDNA  from  total  RNA  isolated  from  peripheral
blood obtained from all members of family A. A fragment of
about 559 bp was obtained, and, as shown in Figure 4, the
cDNA sequencing revealed intron 6 retention in two affected
members (I-1, II-1) and an asymptomatic individual (II-2).
The transversion G/A occurred in the first nucleotide of intron
6, interrupting its splicing and leading to a frameshift and
truncated protein of 186 amino acids with 11 novel amino
acids  before  a  premature  stop.  Figure  5  shows  fundus
photographs documenting four members of family A. The
youngest  sibling  (II-3)  underwent  an  indirect
ophthalmoscopic examination and was found to have a normal
fundus.  However  other  tests;  field  of  vision,  fundus
Figure 4. Electropherograms displaying intron 6 retention. A comparison of a portion of PRPF31 cDNA sequences between the unaffected
(top: I-2) and the affected (bottom: II- 1) revealed intron 6 retention in all affected and asymptomatic individuals of family A. The green
hatched box represents exonic region, and the red rectangular box indicates the start position of intron 6 retention (non-hatched) in the proband.
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in individual II-3 due to very young age.
RP1  and  IMPDH1  screening:  Except  for  a  few
nonpathogenic variations (Table 3), no other variations were
observed in RP1 and IMPDH1. All intronic polymorphisms
encountered  in  this  study  were  analyzed  using  splice  site
prediction software. It was found that none of these changes
were likely to alter RNA splicing.
DISCUSSION
In our screening of RHO, PRPF31, RP1, and IMPDH1 genes
in 101 index patients, we identified three pathogenic changes:
one in RHO and two in PRPF31. In the United States, the
United Kingdom, and Europe, RHO mutations account for
20%–25% of all adRP cases [7]. So far, only limited research
has been performed in India on the genetics of RP hence such
data was not available.
Prior to this study, only two RP-related studies have been
reported using families from India [17,18]. However these
studies did not report the frequency rate of RHO mutations in
isolated/adRP  patients.  Kumaramanickavel  et  al.  [17]
identified an RHO mutation in a family with arRP, whereas
Dikshit et al. [18] mainly focused on the mutations reported
in codons 345 and 347. In the latter study, the whole gene was
not screened and 100 Indian RP patients were recruited from
76  families,  irrespective  of  the  inheritance  of  RP  [18].
Figure 5. Fundus images of I-1, I-2, II-1, and II-2 of family A. The fundus pictures from unaffected members I-2 and II-2 were normal.
However, typical features of retinitis pigmentosa could be well appreciated in affected members I-1 and II-1.The other details of the members
of family A are as follows; Individual I-1 was a 24-year-old female with a history of night blindness since 8 years. Her visual acuity was
counting fingers at 4 meters, and was not improving with glasses (NIG). Fundus examination revealed arteriolar attenuation, bony spicules
with degenerative macular changes, and disc pallor. The electroretinogram (ERG) was nonrecordable, fields were grossly defective. Individual,
I-2 was a 32-year-old male with a vision of 6/6 and normal fundus. Individual II-1 (proband) was a 5-year-old female with a complaint of
night blindness since 6 months. Fundus revealed attenuated vessels, normal disc, dull foveal reflex, and altered retinal sheen. The ERG was
nonrecordable in both the eyes. Individuals II-2 was a 3.5-year-old male with normal vision and fundus. Individual II-3 is a 2-year-old female
with normal fundus. The ERG and visual field test could not be done due to pediatric age.
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detected  in  approximately  2%  of  isolated  RP  cases  thus
suggesting low frequency of RHO mutations in the Indian
population. The observed low frequency of RHO mutations in
the current study could be due to ethnic variation or small
sample size. However since single gross deletions have also
been encountered at a frequency of 0.8% in RHO , the direct
sequencing based method in the current study would have
failed to detect this type of mutation. Another finding is that,
similar to previous reports, the same missense mutation was
identified in an isolated RP patient, who clinically displayed
the sectoral form of RP [19,20].
Two novel disease-causing changes were identified in
PRPF31. Although our sample included patients from all over
India, PRPF31 mutations were identified only in the patients
from  the  northern  region  of  the  country.  The  frameshift
mutation, p.Lys120GlufsX122, was identified in an isolated
RP patient. However, as the proband was not available for
further analysis, we could not assess the penetrance status of
the disease in the family. The second novel mutation identified
was a splice site mutation, IVS6+1G/A. Upon further genetic
Figure 6. Alignment of protein sequences of the PRPF31 protein The wild-type sequence and two identified novel mutants, IVS6+1G/A and
p.Lys120GlufsX122, are shown. Both the mutations resulted in a premature truncation of the protein.
Figure 7. Schematic representation of
PRPF31  and  its  protein  structure.
Illustrated  are  positions  of  reported
mutations (including large deletions) in
human PRPF31 and domain features of
predicted PRPF31 protein. Two novel
PRPF31  mutations  reported  in  this
study  are  depicted  in  bold.  Distance
between  exons  and  domains  are  not
drawn to scale.
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1111analysis  of  other  family  members  of  the  proband  with
IVS6+1G/A, we found the mutation in clinically affected as
well  as  in  a  clinically  normal  individual,  suggesting
incomplete  penetrance  of  the  disease  in  this  pedigree.
Normally the process of splicing occurs at the first nucleotide
of an intron that removes the noncoding region. However, in
this case splicing at the first nucleotide of intron 6 was skipped
due to the transversion of G/A, thus resulting in the retention
of intron 6. Intron retention was confirmed by sequencing
cDNA derived from lymphocyte RNA. The introduction of
novel nucleotides in the coding region altered the open reading
frame, resulting in the premature termination of the protein
with a total of 186 amino acids instead of in the wild-type of
499 amino acids (Figure 6); this change was a novel finding.
The  contribution  of  the  PRPF31  mutations  in  our
population was determined to be 2% in isolated cases and 2%
in adRP cases. The percentage would increase to 4% in adRP,
considering  that  the  isolated  RP  patient  with
p.Lys120GlufsX122  could  be  an  adRP  case  showing
incomplete  penetrance.  In  such  a  case,  the  frequency  of
PRPF31 mutations in adRP was found to be approximately
equal to that reported in the United Kingdom (5%) [21], but
it is more than what has been reported in Spain (2%) [22], and
Japan (2%) [23]. However, the frequency of these mutations
are relatively low when compared to reports from the United
States (8%) [9]. This could be due to the presence of large
deletions, insertions, or genomic rearrangements, which could
not be detected by the current techniques employed in this
study.
The two novel mutations identified in this study result in
the production of protein devoid of nuclear localization signal
(NLS; Figure 7). NLS is located between residue 351–364,
and it is critical for the export of PRPF31 protein from the
cytoplasm to nucleus. Since NLS is absent in both the mutant
proteins, the translocation of the protein from the cytoplasm
into the nucleus is hindered, affecting its spicing function
[24].  Thus,  these  mutations  seem  to  induce  a  pathogenic
mechanism by haploinsufficiency rather than by a dominant
negative effect.
RP1  screening  revealed  a  previously  reported
polymorphism, p.Arg 872 His. Pathogenic changes were not
identified, due to partial screening of the gene. In this study,
we screened only a segment of RP1 comprising of exons 4F,
4G, and 4H because of the occurrence of frequently reported
mutations, p.Arg677X, p.Gln679X, and two other deletions at
codon 765 and 763 in this region. Disease-causing changes in
IMPDH1 were not identified, which implies that IMPDH1
mutations may not be a causative of adRP in our population.
In  summary,  we  identified  three  pathogenic  changes:
p.Gly106Arg  in  RHO,  and  two  novel  mutations,
p.Lys120GlufsX122 and IVS6+1G/A in PRPF31. Causative
mutations were identified in approximately 3% of our study
group. The relative contribution of each gene to the total
number  of  mutations  was  estimated  as  1%  RHO  and  4%
PRPF31. However, we did not identify causative mutations
in RP1 and IMPDH1 .To the best of our knowledge, this is the
first  study  undertaken  to  determine  the  contribution  of
commonly reported adRP genes, RHO, PRPF31, RP1, and
IMPDH1 in RP patients from India.
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